SERA Chief Medical Officer Davis Sells $16K of Stock

Inglis Tiffany Eul Davis, the Chief Medical Officer of Sera Prognostics, Inc. (SERA), sold 8,024 shares on October 12, 2026, at a price of $2.03 per share, totaling about $16,289. This sale was not part of a planned trading arrangement.

Other Institutional Activity in Sera Prognostics

Several institutional investors hold shares in Sera Prognostics. Baker Bros. Advisors, LP maintains 5,498,170 shares valued at approximately $11.3 million. Whetstone Capital Advisors, LLC holds 3,306,889 shares worth about $6.8 million. Aberdeen Group plc increased its stake by 202,784 shares, bringing its total to 2,753,525 shares valued at around $5.7 million. Vivo Capital, LLC continues to hold 1,650,440 shares worth about $3.4 million, while Vanguard Capital Management LLC added 93,680 shares, totaling 1,297,792 shares valued at approximately $2.7 million.

Sera Prognostics, Inc. Stock Up 1.5%

As of October 16, 2026, Sera Prognostics shares traded recently around $2.06, which is above its 52-week low of $1.56 but 47.8% below its 52-week high of $3.95. The stock is currently above its 50-day moving average of $2.05 by about 0.7%, but below its 200-day average of $2.20 by approximately 6.3%.

Recent Earnings

Sera Prognostics reported trailing twelve-month revenue of $70,000 and an EPS of -$0.67. The company has a revenue growth rate of 76.5% year-over-year. The next earnings date is scheduled for November 16, 2026.

Insider Buying and Selling at Sera Prognostics, Inc.

In addition to Davis's recent sale, other insiders have also sold shares. On September 10, 2026, General Counsel Benjamin Jackson sold 2,190 shares at $2.00 each, totaling $4,380. CEO Zhenya Lindgardt also sold 7,022 shares on the same day for $14,044. Officer Dyaarl Lee Anderson Jr. sold 1,800 shares at $2.00 each for $3,600.

About Sera Prognostics

Sera Prognostics, Inc. is a women's health company based in Salt Lake City, UT. It specializes in developing blood-based tests and predictive analytics for pregnancy health, including its PreTRM test, which assesses the risk of premature birth for women carrying a single fetus. This recent insider sale may reflect the company's current market position and insider sentiment.

Bottom Line

Investors should monitor Sera Prognostics as it approaches its next earnings date on November 16, 2026. The recent insider sales, including Davis's transaction, may offer insights into insider perspectives on the company's performance and market conditions.